MedTrace Logo

Telerehabilitation Alzheimer's Disease Feasibility (TADF)

NCT04732182 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2022-05-02

No results posted yet for this study

Summary

This is a pilot RCT with equal arms: experimental arm and (wait list) control arm.

All participants will be in the early stage of Alzheimer's disease and on stable medication. They will all continue with this medication for their 6 months participation.

Experimental group will add weekly training on the experimental device, 5 days a week for 8 weeks. Training will involve therapeutic games aimed primarily at the memory cognitive domain. All participants will receive weekly calls from clinical coordinator and report on medication and overall health. Caregivers will also be enrolled so they support the trials.

Conditions

  • Alzheimer Disease
  • Healthy Aging

Interventions

DEVICE

BrightGo cognitive training

Training on the BrightGo experimental device in the home

DRUG

Standard of Care medication for early Alzheimer's Disease

Participant takes 10 mg of Aricept daily or wears an Exelon 9.5 mg patch and is stable on one of these medications that were prescribed for diagnostic of early Alzheimer's Disease

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Rutgers, The State University of New Jersey

    collaborator OTHER

  • Bright Cloud International Corp

    lead INDUSTRY

Principal Investigators

  • Grigore C. Burdea, PhD · Bright Cloud International

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
65 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-16
Primary Completion
2022-12-31
Completion
2023-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04732182 on ClinicalTrials.gov